Status: Recruiting
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.
Participants needed: 57
Trial details
Phase: Phase 2Age: 3+Biological sex: AllType: InterventionalSponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbHUpdated: May 16, 2024Locations: 31
Eligibility criteria
Histologically confirmed new diagnosis of nasopharyngeal carcinoma according to... [+4]
Newly diagnosed nasopharyngeal carcinoma, Stage I in all patients, Stage II in p... [+31]